1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation
| العنوان: | 1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation |
|---|---|
| المؤلفون: | Vivian Fonseca, Lizheng Shi, Robert Lubwama, Priscilla Hollander, Melvin J. Van Vleet, Eboni G. Price-Haywood, Xuejun V. Peng, Rajeev Ayyagari |
| المصدر: | Diabetes. 68 |
| بيانات النشر: | American Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, Medical record, Basal insulin, medicine.disease, Glucagon-like peptide-1, Obesity, Internal medicine, Cohort, Internal Medicine, medicine, In patient, business, Dyslipidemia, Glycemic |
| الوصف: | This real-world retrospective observational analysis was conducted using data from REACHnet, a U.S. regional electronic medical records (EMR) database. Glycemic outcomes after simultaneous or sequential initiation of basal insulin (BI) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) were evaluated in patients with T2D uncontrolled (A1C ≥7.0%) on oral antidiabetes drugs (OADs). Three patient cohorts were defined: simultaneous BI and GLP-1 RA initiation (Cohort 1; n=109); initiation of BI followed by a GLP-1 RA with a gap of ≤90 days (Cohort 2; n=301); and initiation of BI followed by a GLP-1 RA with a gap of >90 days (Cohort 3; n=459). Baseline mean A1C was very similar across the cohorts (10.3%, 10.3%, and 10.2% in Cohorts 1, 2, and 3, respectively), as were comorbidities including dyslipidemia, hypertension, and obesity. Mean A1C decreased in all 3 cohorts in the 12 months from the date of first BI injection. The greatest mean A1C reductions occurred within 6 months of simultaneous administration (Cohort 1: -2.18%), followed by addition of a GLP-1 RA within 90 days (Cohort 2: -1.77%) and after 90 days (Cohort 3: -1.24%). Results at 12 months were Cohort 1: -1.66%; Cohort 2: -1.46%; and Cohort 3: -1.32%. Persistence (i.e., non-discontinuation of index treatments) at 12 months was 74.3%, 73.8%, and 80.0% in Cohorts 1, 2, and 3, respectively. Simultaneous initiation resulted in more patients achieving A1C In conclusion, this retrospective analysis of real-world EMR data in patients with T2D uncontrolled on OADs suggests that simultaneous initiation of BI and a GLP-1 RA resulted in significantly better glycemic control than sequential initiation with a gap of >90 days. Disclosure X.V. Peng: Employee; Self; Sanofi. Stock/Shareholder; Spouse/Partner; AbbVie Inc. Stock/Shareholder; Self; AbbVie Inc., Sanofi. R. Ayyagari: Consultant; Self; Sanofi US. Other Relationship; Self; Various pharmaceutical companies. R. Lubwama: Employee; Self; Merck & Co., Inc., Sanofi. M.J. Van Vleet: Employee; Self; Sanofi US. L. Shi: None. E.G. Price-Haywood: None. P. Hollander: Advisory Panel; Self; Novo Nordisk Inc. V. Fonseca: Board Member; Self; American Association of Clinical Endocrinologists. Consultant; Self; Abbott, Asahi Kasei Corporation, Novo Nordisk Inc., Sanofi US, Takeda Pharmaceutical Company Limited. Research Support; Self; Bayer US. Stock/Shareholder; Self; Amgen Inc., BRAVO4HEALTH, Mellitus Health. Funding Sanofi U.S. |
| تدمد: | 1939-327X 0012-1797 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::58b9a715c67d144ffe212b59f241d355Test https://doi.org/10.2337/db19-1116-pTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........58b9a715c67d144ffe212b59f241d355 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 |
|---|